Display options
Cite
Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146-1159doi: 10.1111/bjd.20568.
Reich, K., Gordon, K. B., Strober, B. E., Armstrong, A. W., Miller, M., Shen, Y. K., You, Y., Han, C., Yang, Y. W., Foley, P., & Griffiths, C. E. M. (2021). Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. The British journal of dermatology, 185(6), 1146-1159. https://doi.org/10.1111/bjd.20568
Reich, K, et al. "Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2." The British journal of dermatology vol. 185,6 (2021): 1146-1159. doi: https://doi.org/10.1111/bjd.20568
Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021 Dec;185(6):1146-1159. doi: 10.1111/bjd.20568. Epub 2021 Sep 08. PMID: 34105767.
Copy Download .nbib Format: NLM
Share it on

Br J Dermatol. 2021 Dec;185(6):1146-1159. doi: 10.1111/bjd.20568. Epub 2021 Sep 08.

Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.

The British journal of dermatology

K Reich, K B Gordon, B E Strober, A W Armstrong, M Miller, Y K Shen, Y You, C Han, Y W Yang, P Foley, C E M Griffiths

Affiliations

  1. Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  2. Medical College of Wisconsin, Milwaukee, WI, USA.
  3. Yale University, New Haven, CT, USA.
  4. Central Connecticut Dermatology Research, Cromwell, CT, USA.
  5. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  6. Janssen Research & Development, LLC, Spring House, PA, USA.
  7. Janssen Global Services, LLC, Horsham and Malvern, PA, USA.
  8. The University of Melbourne, St Vincent's Hospital Melbourne and Probity Medical Research, Skin Health Institute, Carlton, VIC, Australia.
  9. Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester, UK.

PMID: 34105767 DOI: 10.1111/bjd.20568

Abstract

BACKGROUND: Psoriasis is a chronic disease requiring long-term therapy.

OBJECTIVES: Physician- and patient-reported outcomes were evaluated through week 252 in VOYAGE 1 and VOYAGE 2.

METHODS: In total, 1829 patients were randomized at baseline to receive guselkumab 100 mg every 8 weeks, placebo or adalimumab. Patients receiving placebo crossed over to guselkumab at week 16. Patients receiving adalimumab crossed over to guselkumab at week 52 in VOYAGE 1, and randomized withdrawal and retreatment occurred at weeks 28-76 in VOYAGE 2; all patients then received open-label guselkumab through week 252. Efficacy and health-related quality of life (HRQoL) endpoints were analysed through week 252. Safety was monitored through week 264.

RESULTS: The proportions of patients in the guselkumab group who achieved clinical responses at week 252 in VOYAGE 1 and VOYAGE 2, respectively, were 84·1% and 82·0% [≥ 90% improvement in Psoriasis Area and Severity Index (PASI)]; 82·4% and 85·0% [Investigator's Global Assessment (IGA) 0 or 1]; 52·7% and 53·0% (100% improvement in PASI) and 54·7% and 55·5% (IGA 0). HRQoL endpoints were achieved as follows: 72·7% and 71·1% of patients (Dermatology Life Quality Index 0 or 1: no effect on patient's life); 42·4% and 42·0% [Psoriasis Symptoms and Signs Diary (PSSD) symptom score = 0] and 33·0% and 31·0% (PSSD sign score = 0). As measured in VOYAGE 2 only, approximately 45% of patients achieved ≥ 5-point reduction in Short Form-36 physical and mental component scores, and 80% reported no anxiety or depression (Hospital Anxiety and Depression Scale scores < 8). Similar findings were reported for adalimumab crossovers. These effects were maintained from week 52 in VOYAGE 1 and week 100 in VOYAGE 2. No new safety signals were identified.

CONCLUSIONS: Guselkumab maintains high levels of clinical response and improvement in patient-reported outcomes through 5 years in patients with moderate-to-severe psoriasis.

© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

References

  1. Menter A, Strober BE, Kaplan DH et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019; 80:1029-72. - PubMed
  2. Kimball AB, Jacobson C, Weiss S et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6:383-92. - PubMed
  3. Horn EJ, Fox KM, Patel V et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57:963-71. - PubMed
  4. Wu Y, Mills D, Bala M. Impact of psoriasis on patients’ work and productivity: a retrospective, matched case-control analysis. Am J Clin Dermatol 2009; 10:407-10. - PubMed
  5. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146:891-5. - PubMed
  6. Wu JJ, Penfold RB, Primatesta P et al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol 2017; 31:1168-75. - PubMed
  7. Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011; 164 (Suppl. 1):1-14. - PubMed
  8. Blauvelt A, Papp KA, Griffiths CEM et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76:405-17. - PubMed
  9. Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418-31. - PubMed
  10. Griffiths CEM, Papp KA, Song M et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J Dermatolog Treat 2021; https://doi.org/10.1080/09546634.2020.1782817. - PubMed
  11. Reich K, Armstrong AW, Foley P et al. Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study. Am J Clin Dermatol 2020; 21:881-90. - PubMed
  12. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44. - PubMed
  13. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16. - PubMed
  14. Feldman SR, Mathias SD, Schenkel B et al. Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the Psoriasis Symptoms and Signs Diary. J Dermatol Dermatolog Surg 2016; 20:19-26. - PubMed
  15. Mathias SD, Feldman SR, Crosby RD et al. Measurement properties of a patient reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary. J Dermatolog Treat 2016; 27:322-7. - PubMed
  16. Armstrong A, Puig L, Langley R et al. Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. J Dermatolog Treat 2019; 30:27-34. - PubMed
  17. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I: conceptual framework and item selection. Med Care 1992; 30:473-83. - PubMed
  18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-70. - PubMed
  19. Lerner D, Amick BC 3rd, Rogers WH et al. The work limitations questionnaire. Med Care 2001; 39:72-85. - PubMed
  20. Samsa G, Edelman D, Rothman ML et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15:141-55. - PubMed
  21. Gordon KB, Armstrong AW, Foley P et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Invest Dermatol 2019; 139:2437-46. - PubMed
  22. Blauvelt A, Tsai T-F, Langley RG et al. Consistent safety profile with up to five years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol 2021; in press - PubMed
  23. Blauvelt A, Lebwohl MG, Mabuchi T et al. Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol 2021; 85:360-8. - PubMed
  24. Lebwohl MG, Blauvelt A, Menter A et al. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, open-label, phase II study. Am J Clin Dermatol 2019; 20:863-71. - PubMed
  25. Yiu ZZN, Mason KJ, Hampton PJ et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol 2020; 183:294-302. - PubMed
  26. Menter A, Papp KA, Gooderham M et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol 2016; 30:1148-58. - PubMed

Publication Types